Synergistic combination for potent delivery1,2
Based on animal studiesa…

Increased activity vs free drug
The synergistic 1:5 molar ratio of daunorubicin and cytarabine has been shown to enhance the killing of leukemia cells in vitro and in murine models1

Greater leukemia cell uptake
VYXEOS liposomes enter the bone marrow and are preferentially taken up by leukemia cells to a greater extent than by normal bone marrow cells in a murine model1,3
- Their unique composition allows the negatively charged VYXEOS liposomes to interact with receptors that are overexpressed by leukemic cells compared to the expression by normal bone marrow cells3,4
Based on pharmacokinetic Phase 1 trial data…

Prolonged delivery
The longer half-life of VYXEOS resulted in greater drug exposure within the plasma and bone marrow than traditional chemotherapy1,5
- Estimated median half-life of daunorubicin was 32 hours with VYXEOS vs 19 hours as free drug1,6
- Estimated median half-life of cytarabine was 40 hours with VYXEOS vs approximately 1 to 3 hours as free drug1,7
aThe clinical relevance of this is unknown.